Lupin Limited, a global pharmaceutical leader, has acquired three anti-diabetes trademarks—GIBTULIO®, GIBTULIO MET®, and AJADUO®—from Boehringer Ingelheim International GmbH. The acquisition is expected to strengthen Lupin’s diabetes treatment portfolio in India, where approximately 80 million adults have diabetes.
Lupin has been co-marketing these drugs in India since 2016. The medications, part of the SGLT-2 inhibitor class, include:
- GIBTULIO® (empagliflozin): Improves glycemic control and reduces cardiovascular risks in adults with type 2 diabetes.
- GIBTULIO MET® (empagliflozin + metformin): Combines two effective diabetes treatments for enhanced results.
- AJADUO® (empagliflozin + linagliptin): A dual-action drug for better glycemic control and cardiovascular protection.
As per the agreement, trademark rights will be transferred to Lupin by March 2025. Speaking about the acquisition, Nilesh Gupta, Managing Director of Lupin, said, “This move reaffirms our commitment to delivering affordable and effective treatments for diabetes patients in India.”
Rajeev Sibal, President – India Region Formulations, highlighted the need for accessible treatments, adding, “With the increasing prevalence of diabetes, this acquisition allows us to meet patient needs with innovative and cost-effective solutions.”
India has a staggering diabetes burden, with 80 million adults diagnosed and an additional 25 million considered pre-diabetic. Many remain undiagnosed, which leads to complications such as heart attacks and strokes.
